Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Volume 4, Issue 5, October 2020, Pages 586-587
Letter to the editorDeselecting Melanoma Patients for Sentinel Lymph Node Biopsy During COVID-19: Clinical Utility of Tumor Molecular Profiling
Under a Creative Commons license
open access
Cited by (0)
Potential Competing Interests: Dr Meves reports a financial interest in a molecular test (CP-GEP) being developed by SkylineDx in the area of melanoma. Mayo Clinic has reviewed this relationship and taken appropriate steps to protect the scientific integrity of the research. Dr Eggermont has an equity stake in SkylineDx.
Grant Support: Supported by the National Cancer Institute: grant CA215105.
© 2020 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.